Introduction
Kraepelin described what we now call bipolar disorder (BD) as a periodic disease with symptom-free intervals and a good outcome. 1 However, recent studies have suggested that the reality is substantially different.
Prospective studies with large samples have shown that BD is characterized by a chronic course, persistence of symptoms for most of the time 2, 3 and frequent recurrence despite adequate treatment. 4 Moreover, although the diagnosis is made after a manic episode, 5 there is a predominance of depressive symptoms along the course of the disease. These symptoms have a subsyndromal intensity most of the times, 2 which has been associated with the impact that BD has, particularly on occupational and social functioning. 6, 7 Several longitudinal prospective studies have already investigated the course of BD, 2,7-9 but most included American and European samples, and, to our knowledge, no similar studies have been conducted in Latin America. 
Clinical evaluation
The patients were treated in a naturalistic follow- Every month, each patient was evaluated by the same examiner, the assisting physician, to ensure reliability.
Moreover, each physician was previously trained by the senior investigator to use the Young Mania Rating Scale (YMRS) 11 and the Hamilton Depression Scale (HAM-D17). 12 However, interexaminer agreement was not evaluated. The number of months with euthymic, manic, depressive and mixed moods was defined according to the DSM-IV-TR criteria 5 ; manic symptoms were evaluated using the YMRS, 11 and depressive symptoms, the HAM-D17. 12 The mixed state months were conventionally defined as those when the patient had at least two manic symptoms and at least two depressive symptoms. Months of euthymic mood were those when the criteria to define manic and major depressive episodes were not met.
The other outcome measures were intensity of manic and depressive symptoms, according to the monthly application of the YMRS 11 and the HAM-D17. 12 Mean total scores were calculated for the 12 months of followup for each patient. In addition, time free of psychotic symptoms was defined according to clinical observation.
Finally, we studied whether the outcomes of 
Statistical analysis
The Table 1 shows the demographic and retrospective clinical data of the 102 patients that completed the 12-month follow-up. Our sample comprised a large number of women, and there was a broad variation in age; the level of education was relatively high, as most patients has at least 11 years of schooling; and less than 50% of the patients had a partner.
Sample characteristics and retrospective clinical data

Variable Results
Age, mean ± standard deviation 43.36±12. 
Clinical progression
The drugs prescribed during the prospective 12-month follow-up were: lithium, 65.7% (n = 67); anticonvulsants (valproic acid, carbamazepine, oxcarbazepine, lamotrigine or topiramate), 67.6% (n = 69); antidepressants, 41.2% (n = 42); antipsychotics, 77.5% (n = 79); benzodiazepines, 68.6% (n = 70); and thyroid hormone, 9.8% (n = 10). No patient underwent electroconvulsive therapy. Table 2 shows total time with euthymic, manic and depressive symptoms in the group of 102 patients during the 12-month follow-up, as well as the duration of psychotic symptoms.
Only 5.8% (n = 6) of the participants remained euthymic along all the 12 months, whereas 21.6% (n = 22) had symptoms during all the study. A total of 43.1%
were symptomatic for at least half of the time. Patients remained euthymic for a mean 4.9±4.1 months.
Depressive symptoms were felt at some time by 75.5% (n = 77) of the patients; in 6.9% (n = 7), they occurred for at least half of all the study time. The patients had depressive symptoms for a mean 3.6±3.5 months.
Manic symptoms were felt by 54.9% (n = 56) of the participants; 6.9% (n = 7) of the patients had manic symptoms at least half of all the study time.
No patients had manic symptoms during all the 12 months: mean time with manic symptoms was 1.7±2.3
months.
The evaluation of the intensity of the manic symptoms revealed that the mean YMRS 11 score in the whole sample was 5.2±4.3. The mean HAM-D17 12 score of intensity of depressive symptoms was 6.8±4.8.
Mixed moods were found at some time in 49% (n = 50) of the patients, and 11.8% (n = 12) persisted for at least half of the study time. The patients had a mixed mood for a mean 1.8±2.6 months.
Psychotic symptoms were found for a mean 1.3±2.4 months in only 39.2% (n = 40) of the sample. Only seven patients had to be hospitalized, one of them twice.
One patient attempted suicide during the prospective 12-month follow-up. Comorbidities were found in 43.1% of the patients (n = 44): obsessive compulsive disorder (13.7%; n = 14), social (12.8%; n = 13) and specific (9.8%; n = 10) phobias, panic disorder (9.8%; n = 10), mostly associated with agoraphobia (n = 7), eating disorders (7.8%; n = 8), alcohol abuse and dependence (7.8%; n = 8 -abuse: n = 4; dependence: n = 4); cocaine abuse and dependence (5%; n = 5 -abuse: n = 4; dependence: n = 2), generalized anxiety disorder (2.9%; n = 3), post-traumatic stress disorder (2.9%; n = 3), epilepsy (2%; n = 2), somatoform disorder (1%; n = 1), and conversion disorder (1%; n = 1).
Factors associated with progression
Previously taken medication included: lithium (56.9%; n = 58) anticonvulsants (valproic acid, carbamazepine, oxcarbazepine, lamotrigine or topiramate) (78.4%; n = 80), antidepressants (60.8%; n = 62), antipsychotics (76.5%; n = 78) and benzodiazepines (69.6%; n = 71).
Nine patients (8.8%) had undergone electroconvulsive therapy, and 21.5% (n = 22) had not undergone any previous treatment.
Other authors also found that symptoms persisted for a significant length of the course of the disease.
2-4,8,9
Judd et al. 2 prospectively followed up 146 patients with BD type I for 12 to 20 years and found that the patients remained asymptomatic for half of the disease course.
Moreover, subsyndromal symptoms were present for a longer time than full affective episodes. Post et al. 3 followed up 258 patients with BD, most type I, for one year and found that almost half (40.7%) of the patients was moderately ill (symptomatic for more than 25%
and less than 75% of the follow-up time) and more than one fourth were severely ill (symptomatic for more than 75% of the time). For two years, Perlis et al. 4 followed up 1,469 patients, who received "the best possible treatment". Despite that, only a little more than half of the sample achieved recovery, and of those who did, almost half had recurrences.
Still in agreement with our findings, the predominance of depressive symptoms over manic and mixed moods along the course of the disease has also been reported in other studies, 2, 4, 8, 9 and some authors found that psychotic symptoms are not very frequent. 2, 13 In our study, a longer 
No. of patients
Total time with euthymic symptoms ≥ 75% 26 ≥ 50% and < 75% 18 ≥ 25% and < 50% 19
< 25% 39
Total time with manic symptoms ≥ 75% 2 ≥ 50% and < 75% 5 ≥ 25% and < 50% 17
< 25% 78
Total time with mixed symptoms ≥ 75% 3 ≥ 50% and < 75% 9 ≥ 25% and < 50% 15
< 25% 75
Total time with depressive symptoms ≥ 75% 14 ≥ 50% and < 75% 12 ≥ 25% and < 50% 28
< 25% 48
Total time with psychotic symptoms ≥ 75% 3 ≥ 50% and < 75% 8 ≥ 25% and < 50% 7 < 25% 84 Table 2 -Clinical progression has been linked to method differences, 34 as there are different criteria to define a poor outcome, such as total symptomatic time, time to recurrence and others.
One of the limitations of our study was the severity of patient disease, as they were followed up in a BD outpatient research department. Therefore, our sample may fail to represent all individuals that have BD. In our outpatient research department, we see seriously affected patients referred by other institutions, as well as patients referred directly after hospitalization. In contrast, a large number of the patients under treatment
were excluded from the sample because they did not keep the monthly attendance to visits during the study time. We believe that some of them were patients with more severe disease. Therefore, as this sample excluded a large number of patients that were not able to keep their regular follow-up, the patients selected may not represent the population of interest, a fact that may affect the internal validity of this study. Moreover, the patients excluded from the study had a lower socioeconomic status than those that were included, which may complicate the generalization of our study findings for this population. 
Conclusion
In agreement with other studies, our findings showed that BD outcomes seem to be poor, even when the patients are followed up in research centers and and early onset. 17, 21, 22 Other authors have suggested that previous depressive episodes might predict a progression with more depressive symptoms, whereas previous manic episodes might predict a progression with more manic symptoms. In this sense, Nolen et al. 14 found that a greater intensity of depressive and manic symptoms is associated with a high number of previous depressive and manic episodes. Daban et al., 17 however, found that, in agreement with our findings, depressive polarity of first episode was a good predictor of greater chronicity and of predominance of depressive polarity of subsequent episodes.
Therefore, greater attention has been drawn to the theory created by Angst, 23 of a polarity predominance in patients with BD. [24] [25] [26] According to that theory, some patients tend to have twice or more manic than depressive episodes, whereas the opposite is true for some other patients. Such type of predominance seems to be found in about half of the patients with BD. 24 Still according to that theory, the predominance of depressive episodes is more frequent than that of manic episodes 25, 26 and is be associated with poorer outcomes. [24] [25] [26] Differently from other studies, we did not find any correlation between outcome and psychotic symptoms 4, 15, 16, [27] [28] [29] [30] or number of previous hospitalizations. 31, 32 However, contradictions about which factors predict outcomes are frequent in the literature. [13] [14] [15] 31, 33 The major reason of this inconsistency and higher number of previous depressive episodes predict the occurrence of new depressive episodes and their greater intensity. Therefore, more effective BD treatments should be developed, particularly for the management of depressive episodes, as they seem to have a greater impact on outcome. In the same line,
we plan future studies to investigate the occurrence of polarity predominance during the course of the disease and to evaluate factors that predict outcome in subgroups according to retrospective clinical differences.
